| scholarly article | Q13442814 |
| P50 | author | Constantine G. Lyketsos | Q91213781 |
| Peter V. Rabins | Q112424479 | ||
| Jerome Yesavage | Q87854494 | ||
| Bruce G Pollock | Q90130236 | ||
| P2093 | author name string | Daniel Weintraub | |
| Lon S Schneider | |||
| Curtis L Meinert | |||
| Paul B Rosenberg | |||
| Lea T Drye | |||
| Jacobo E Mintzer | |||
| D P Devanand | |||
| Anton P Porsteinsson | |||
| Constantine Frangakis | |||
| Cynthia A Munro | |||
| Zahinoor Ismail | |||
| Christopher Marano | |||
| CitAD Research Group | |||
| Gregory Pelton | |||
| P2860 | cites work | Serotonin 5-HT2A and 5-HT6 receptors in the prefrontal cortex of Alzheimer and normal aging patients | Q24554505 |
| Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial | Q24555726 | ||
| “Mini-mental state” | Q25938989 | ||
| Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease | Q27860795 | ||
| Random-effects models for longitudinal data | Q28279619 | ||
| A positron emission tomography study of 5-hydroxytryptamine-1A receptors in Alzheimer disease | Q28306131 | ||
| Systematic review of psychological approaches to the management of neuropsychiatric symptoms of dementia. | Q30351745 | ||
| A simulation study evaluating approaches to the analysis of ordinal outcome data in randomized controlled trials in traumatic brain injury: results from the IMPACT Project | Q33531383 | ||
| Sertraline for the treatment of depression in Alzheimer disease: week-24 outcomes | Q33539531 | ||
| The neurobehavioural rating scale: assessment of the behavioural sequelae of head injury by the clinician | Q33627214 | ||
| Sertraline for the treatment of depression in Alzheimer disease | Q33741090 | ||
| Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study | Q34100750 | ||
| Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients | Q34116373 | ||
| An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. | Q34433716 | ||
| Risk of death in elderly users of conventional vs. atypical antipsychotic medications | Q34471609 | ||
| Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. | Q34573456 | ||
| Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials | Q34651137 | ||
| The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial | Q34920191 | ||
| Sensorimotor changes and functional performance in patients with knee osteoarthritis. | Q35546975 | ||
| Neuroleptic drugs in dementia: benefits and harm | Q36484553 | ||
| Association of antipsychotic use with hospital events and mortality among medicare beneficiaries residing in long-term care facilities | Q37172915 | ||
| Management of agitation and aggression associated with Alzheimer disease | Q37504709 | ||
| A metaanalysis of controlled trials of neuroleptic treatment in dementia | Q37586446 | ||
| Management of behavioral problems in Alzheimer's disease | Q37680018 | ||
| The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia | Q39605807 | ||
| Neurochemical studies of Alzheimer's disease | Q41443844 | ||
| Conceptualization of agitation: results based on the Cohen-Mansfield Agitation Inventory and the Agitation Behavior Mapping Instrument | Q41473169 | ||
| Behavioral and psychological signs and symptoms of dementia: a consensus statement on current knowledge and implications for research and treatment | Q41473213 | ||
| Anticonvulsants in the treatment of aggression in the demented elderly: an update | Q42081136 | ||
| Effect of antipsychotics on mortality in elderly patients with dementia: a 1-year prospective study in a nursing home. | Q43523506 | ||
| A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia | Q43632183 | ||
| A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting | Q43885713 | ||
| Reduced serotonin 5-HT1A receptor binding in the temporal cortex correlates with aggressive behavior in Alzheimer disease | Q44438171 | ||
| Patient predictors of response to treatment of depression in Alzheimer's disease: the DIADS study | Q44753025 | ||
| Association of the serotonin transporter and receptor gene polymorphisms in neuropsychiatric symptoms in Alzheimer disease | Q45020335 | ||
| Persistence of and changes in neuropsychiatric symptoms in Alzheimer disease over 6 months: the LASER-AD study | Q45137993 | ||
| Cholinergic-serotonergic imbalance contributes to cognitive and behavioral symptoms in Alzheimer's disease. | Q45262354 | ||
| Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study | Q46193667 | ||
| Serotonin transporter gene polymorphism and BPSD in mild Alzheimer's disease | Q46867874 | ||
| 5-HT2A T102C receptor polymorphism and neuropsychiatric symptoms in Alzheimer's disease | Q47307217 | ||
| Presynaptic serotonergic markers in community-acquired cases of Alzheimer's disease: correlations with depression and neuroleptic medication | Q47633454 | ||
| Serotonergic pathology is not widespread in Alzheimer patients without prominent aggressive symptoms | Q48440546 | ||
| Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia resulting from Alzheimer disease | Q48481063 | ||
| Design of Depression in Alzheimer's Disease Study-2. | Q50920698 | ||
| Verification of scale sub-domains in elderly patients with dementia: a confirmatory factor-analytic approach. | Q51952300 | ||
| Neither atypical nor conventional antipsychotics increase mortality or hospital admissions among elderly patients with dementia: a two-year prospective study. | Q51975736 | ||
| A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. | Q51981345 | ||
| Long-term treatment of elderly individuals with emotional disturbances: an open study with citalopram. | Q53217296 | ||
| Treatment of agitation in AD: a randomized, placebo-controlled clinical trial. | Q53239062 | ||
| The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. A Nordic multicentre study. | Q54088275 | ||
| Methodological issues in characterizing treatment response in demented patients with behavioral disturbances | Q73439034 | ||
| Introduction to behavioural and psychological symptoms of dementia (BPSD) | Q73682662 | ||
| A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia | Q81228549 | ||
| The course of neuropsychiatric symptoms in dementia. Part I: findings from the two-year longitudinal Maasbed study | Q81791704 | ||
| P433 | issue | 2 | |
| P921 | main subject | Alzheimer's disease | Q11081 |
| P304 | page(s) | 121-130 | |
| P577 | publication date | 2012-02-01 | |
| P1433 | published in | Alzheimer's and Dementia | Q15750965 |
| P1476 | title | Citalopram for agitation in Alzheimer's disease: design and methods | |
| P478 | volume | 8 |
| Q38544531 | Advancements in the treatment of agitation in Alzheimer's disease |
| Q39181686 | An update on the advancements in the treatment of agitation in Alzheimer's disease |
| Q57166448 | Antidepressants for treating depression in dementia |
| Q36345261 | Change in agitation in Alzheimer's disease in the placebo arm of a nine-week controlled trial |
| Q46757500 | Changes in Neuropsychiatric Inventory Associated with Semagacestat Treatment of Alzheimer's Disease |
| Q28539543 | Changes in QTc interval in the citalopram for agitation in Alzheimer's disease (CitAD) randomized trial |
| Q53389682 | Characterizing Highly Benefited Patients in Randomized Clinical Trials. |
| Q37514278 | Citalopram for the Treatment of Agitation in Alzheimer Dementia: Genetic Influences |
| Q48074100 | Depression and Suicidal Ideation During Two Psychosocial Treatments in Older Adults with Major Depression and Dementia |
| Q36109984 | Designing a trial to evaluate potential treatments for apathy in dementia: the apathy in dementia methylphenidate trial (ADMET). |
| Q33863623 | Effect of citalopram on agitation in Alzheimer disease: the CitAD randomized clinical trial |
| Q61814798 | Effect of memantine combined with citalopram on cognition of BPSD and moderate Alzheimer's disease: A clinical trial |
| Q90527771 | Escitalopram for agitation in Alzheimer's disease (S-CitAD): Methods and design of an investigator-initiated, randomized, controlled, multicenter clinical trial |
| Q35737687 | Evaluation of a hospital-based day-structuring exercise programme on exacerbated behavioural and psychological symptoms in dementia--the exercise carrousel: study protocol for a randomised controlled trial |
| Q40974255 | Heterogeneity of Treatment Response to Citalopram for Patients With Alzheimer's Disease With Aggression or Agitation: The CitAD Randomized Clinical Trial. |
| Q35185368 | Medication development for agitation and aggression in Alzheimer disease: review and discussion of recent randomized clinical trial design |
| Q42655602 | Neuropsychiatric signs and symptoms of Alzheimer's disease: New treatment paradigms |
| Q36385255 | Neuropsychiatric symptoms as early manifestations of emergent dementia: Provisional diagnostic criteria for mild behavioral impairment |
| Q42744109 | Principal components analysis of agitation outcomes in Alzheimer's disease |
| Q36063264 | Principles and management of neuropsychiatric symptoms in Alzheimer's dementia |
| Q36087892 | Progress in Treatment Development for Neuropsychiatric Symptoms in Alzheimer's Disease: Focus on Agitation and Aggression. A Report from the EU/US/CTAD Task Force |
| Q34675960 | Role of citalopram in the treatment of agitation in Alzheimer's disease |
| Q34370011 | Safety and efficacy of methylphenidate for apathy in Alzheimer's disease: a randomized, placebo-controlled trial |
| Q36553622 | Sedation mediates part of Citalopram's effect on agitation in Alzheimer's disease |
| Q38209851 | Serotonergic therapies for cognitive symptoms in Alzheimer's disease: rationale and current status. |
| Q89406773 | Sex Differences in the Neuropsychiatric Symptoms of Patients With Alzheimer's Disease |
| Q41558769 | Structured physical exercise improves neuropsychiatric symptoms in acute dementia care: a hospital-based RCT |
| Q35735566 | Time to Response to Citalopram Treatment for Agitation in Alzheimer Disease |
| Q36213419 | Treatment-resistant depression in later life |
| Q99544105 | What the COVID pandemic entails for the management of patients with behavioral and psychological symptoms of dementia: experience in France |
Search more.